Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Nov 30;187(5):669–683. doi: 10.1083/jcb.200906014

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2009 Rucci et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jcb.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 1. — Effect of ^hbdPRELP on osteoclastogenesis and bone resorption. (A and B) Unfractionated mouse bone marrow cells were incubated in the presence of 1,25(OH)₂VitaminD₃ with vehicle, 15 µM ^hbdPRELP, or 15 µM of control peptide (A) or with the indicated concentrations of ^hbdPRELP (B). Osteoclasts were then stained for TRAcP, enumerated, and expressed as the percentage of vehicle treated. (C) Pit index of cells cultured as in A but onto bone slices. (D) Bone marrow macrophages were incubated for 6 d with 50 ng/ml M-CSF and 120 ng/ml RANKL plus vehicle or 15 µM ^hbdPRELP. Osteoclasts were then assessed by TRAcP staining (top) and enumerated (bottom). (E) Bone marrow macrophages were treated with 15 µM of control peptide, 15 µM ^hbdPRELP, or 15 µM of intact PRELP, and osteoclastogenesis was assessed as described in A. (A–E) Results are the mean ± SEM of three independent experiments (*, P < 0.01).